Evangelos Giamarellos-Borboulis

National and Kapodistrian University of Athens, Greece

He is Professor of Internal Medicine and Infectious Diseases at the Medical School of the National and Kapodistrian University of Athens since 2018. He was trained in the Immunology of Infections at the Department of Internal Medicine and Infectious Disease of Radboud University in the Netherlands. In 2012 and 2013 he served as guest Professor of the Department of Critical Care Medicine of Jena University Hospital in Germany. His main research contribution is immunomodulation in sepsis and in auto-inflammatory disorders for which he was awarded the Young Investigator Research Award by the European Society of Clinical Microbiology and Infectious Diseases. He has 508 publications in international peer-reviewed journals with more than 31,000 citations and h-index 85. He has contributed in the development of clarithromycin for immunomodulatory treatment of septic shock, the recognition of hidradenitis suppurativa (HS) as an auto-inflammatory disorder and in the licensing of adalimumab for treatment of (HS). He is the current chairman of the European Sepsis Alliance. His main achievement is the approval of anakinra for COVID-19 pneumonia in adults by the European Medicines Agency and the Food and Drug Administration through the phase 2 and 3 trials SAVE and SAVE-MORE that he designed and conducted.